How should azathioprine-induced neutropenia be managed?

Management of Azathioprine-Induced Neutropenia

Azathioprine should be promptly reduced or stopped if there is significant bone marrow depression, with immediate withdrawal required for neutrophil counts below 1.0 × 10⁹/L. 1

Immediate Action Based on Neutrophil Count

The management approach depends on the severity of neutropenia:

Mild Neutropenia (Downward Trend but Within Normal Range)

• Increase monitoring frequency with continued vigilance in haematological assessment
• Consider dose reduction as a precautionary measure
• Continue close observation with more frequent complete blood counts 2

Moderate Neutropenia (Below Normal Range but >1.0 × 10⁹/L)

• Reduce azathioprine dose immediately
• Intensify monitoring with weekly complete blood counts
• Consider measuring azathioprine metabolites to assess drug metabolism 1

Severe Neutropenia (Neutrophil Count <1.0 × 10⁹/L)

• Immediately discontinue azathioprine 2
• Manage jointly with a haematologist for platelet counts <50 × 10⁹/L or neutrophil counts <1.0 × 10⁹/L 2
• Monitor for signs of infection (unexplained fever, sore throat, ulceration)
• Consider granulocyte colony-stimulating factor (G-CSF) if severe neutropenia persists 3

Important caveat: The nadir of blood counts may occur 8 days after stopping azathioprine before recovery begins, so continued close monitoring is essential even after drug discontinuation 4.

Genetic Testing Considerations

If severe myelosuppression occurs, consider genetic testing:

• TPMT (thiopurine methyltransferase) deficiency testing - though note that 73% of patients with severe myelosuppression have normal TPMT activity 5
• NUDT15 gene mutation testing - particularly important as this can cause severe neutropenia independent of TPMT status 6, 7, 8
• ITPA gene mutation may also contribute to azathioprine-induced neutropenia, especially in Asian patients with chronic kidney disease 7

Critical point: Normal TPMT activity does NOT exclude risk of severe neutropenia, as most cases occur in patients with normal enzyme activity 5, 4. Genetic testing cannot substitute for regular blood count monitoring 6.

Monitoring After Discontinuation

• Continue weekly complete blood counts until neutrophil recovery is documented
• Expect gradual improvement, with potential worsening before recovery begins
• Monitor for secondary infections during the neutropenic period
• If fever develops with severe neutropenia, initiate early empirical broad-spectrum antibiotics immediately 9, 3

Alternative Immunosuppression

Once azathioprine is discontinued for significant bone marrow suppression:

• Do NOT rechallenge with azathioprine, as reactions are typically more severe upon re-exposure 2
• Consider mycophenolate mofetil as an alternative immunosuppressant, particularly in patients with TPMT deficiency 1
• Evaluate other treatment options based on the underlying condition (methotrexate, biologics, etc.)

Drug Interactions That Increase Risk

Be aware that certain medications significantly increase neutropenia risk when combined with azathioprine:

• Allopurinol or febuxostat (xanthine oxidase inhibitors) - require dose reduction to 1/3-1/4 usual dose or avoidance 6
• Aminosalicylates (sulfasalazine, mesalazine, olsalazine) - inhibit TPMT and potentiate toxicity 6
• Ribavirin - causes severe pancytopenia through IMDH inhibition 6
• Co-trimoxazole and other myelosuppressive drugs 2
• ACE inhibitors - reported to induce severe leukopenia when combined with azathioprine 6

The most recent and authoritative guidance from the 2025 British Society of Gastroenterology guidelines 1 emphasizes that azathioprine-induced bone marrow depression requires prompt action, with the severity of neutropenia dictating whether dose reduction or complete withdrawal is necessary.